Jan 07, 2026
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®VIEW RELEASE
Dec 03, 2025
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric ConditionsVIEW RELEASE
Nov 12, 2025
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s DiseaseVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Jan 09, 2026 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
2.01
CHANGE
0.01 (0.5%)
